Early Versus Late Adjunctive Vasopressin in Septic Shock
Sponsor: The Cleveland Clinic • ClinicalTrials.gov ID: NCT06709573
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The goal of the CASPER-Pilot study is to develop clinical decision support (CDS) technology within Epic to randomize patients with septic shock to early versus standard of care vasopressin initiation. The primary aim of this study will be to test the hypothesis that CDS technology can be utilized to create two distinct cohorts of patients reflecting different times of vasopressin initiation based on norepinephrine dose requirements. Secondarily, this study will evaluate the proportion of patients whose norepinephrine dose at the time of vasopressin initiation is within the specified range for the intervention arm they were randomized to. Other outcomes of evaluation will include adherence to the developed CDS technology and comparison of clinical outcomes between the two treatment arms.
Interventions
-
vasopressin - early initiation
(Drug)
BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 10-20 mcg/min
-
vasopressin - standard initiation
(Drug)
BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 20-35 mcg/min
Eligibility criteria
Conditions
Locations
- Cleveland Clinic — Cleveland, Ohio, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record